
FDA Approves Augtyro™ for NTRK-Positive Solid Tumors
Bristol Myers Squibb (NYSE: BMY) has announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Augtyro™ (repotrectinib) for treating adult and pediatric patients aged 12 and…












